Status:
ACTIVE_NOT_RECRUITING
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
Lead Sponsor:
The Netherlands Cancer Institute
Collaborating Sponsors:
Erasmus Medical Center
UMC Utrecht
Conditions:
Stomach Neoplasm
Peritoneal Carcinomatosis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
A randomized controlled two-armed phase III trial for gastric cancer patients with peritoneal dissemination. Randomization between gastrectomy + cytoreductive surgery + HIPEC (experimental arm) and pa...
Detailed Description
Rationale: For gastric cancer patients with peritoneal carcinomatosis palliative systemic chemotherapy is the standard treatment in the Netherlands. There are no potentially curative treatment options...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Biopsy proven primary adenocarcinoma (or undifferentiated carcinoma) of the stomach. Including tumours at the oesophagogastric junction provided that the bulk of the tumour is located in the stomach, and, the intended surgical treatment is a gastric resection and not an oesophagectomy. A high intra-thoracic anastomosis is allowed, but not if a thoracotomy is necessary.
- cT3-cT4 tumour (TNM classification, 7th edition), considered to be resectable (including lymph nodes)
- Limited peritoneal carcinomatosis (PCI \<7) and/ or tumour positive peritoneal cytology confirmed by laparoscopy or laparotomy and proven by pathological examination
- Treatment with systemic chemotherapy, with the latest course ending within 8 weeks prior to inclusion. All currently standard chemotherapy regimens are acceptable
- Absence of disease progression during systemic chemotherapy (prior to inclusion)
- WHO performance status 0-2
- Adequate bone marrow, hepatic and renal function. Minimally acceptable laboratory values at start of the study inclusion:
- ANC ≥ 1.5 x 109 /L
- Platelet count ≥ 100 x 109 /L
- Serum bilirubin ≤ 1.5 x ULN, and ALAT and ASAT ≤ 2.5 x ULN
- Creatinine clearance ≥ 50 ml/min (measured or calculated by Cockcroft-Gault formula)
- For female patients who are not sterilised or in menopause (i.e., amenorrhea ≥1 year if age ≥60 years, or ≥2 years if age \<60 years):
- negative pregnancy test (urine/serum)
- no breast feeding or active pregnancy ambition
- reliable contraceptive methods
- Signed informed consent
Exclusion
- Distant metastases (e.g., liver, lung, para-aortic lymph nodes; i.e., stations 14 and 16) or small bowel dissemination
- Recurrent gastric cancer
- Prior resection of the primary gastric tumour
- Non-synchronous peritoneal carcinomatosis
- Current other malignancy (other than cervix carcinoma and basalioma)
- Uncontrolled infectious disease or known infection with Human Immunodeficiency Virus type -1 or -2
- A known history of hepatitis B or C with active viral replication
- Recent myocardial infarction (\< 6 months) or unstable angina
- Any medical condition not yet specified above that is considered to interfere with study procedures, including adequate follow-up and compliance and/or would jeopardise safe treatment
- Known hypersensitivity for any of the applied chemotherapeutic agents and/or their solvents
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT03348150
Start Date
October 1 2017
End Date
October 1 2027
Last Update
July 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Antoni van Leeuwenhoek/ Netherlands Cancer institute
Amsterdam, Netherlands, 1066CZ